At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Apr 1, 2026 at 16:01 ET
Celldex Therapeutics announced a public offering of its common stock, with underwriters granted a 30-day option to purchase up to an additional 15% of shares. The offering is intended to fund commercial readiness for barzolvolimab, clinical development, platform expansion, and general corporate purposes. Exact size, pricing, and terms remain undisclosed and dependent on market conditions.
- Celldex Therapeutics (CLDX) has commenced an underwritten public offering of common stock.
- Underwriters have a 30-day option to purchase up to an additional 15% of shares.
- Proceeds will fund commercial launch readiness for barzolvolimab (if approved), clinical development, platform growth, and general corporate purposes.
- Leerink Partners and TD Cowen are joint bookrunning managers.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access